CHIMERGEN Trademark

Pharmaceutical preparations for targeted protein degradation, comprising small molecules, peptides, biologics, antibodies designed for the treatment of cancer, autoimmune diseases, inflammatory conditions, central nervous system (CNS) disorders, and other human diseases; pharmaceutical preparations for degrading disease-causing and pathogenic proteins via lysosomal targeting, ubiquitin-proteasome pathways, or other cellular degradation mechanisms; therapeutic agents for the prevention and treatment of neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, and Huntington’s disease; pharmaceutical preparations for the treatment of chronic and acute pain conditions, including neuropathic pain and inflammatory pain; pharmaceutical preparations for the treatment of immune-mediated diseases, including rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis; Pharmaceutical preparations for the treatment of lysosomal storage disorders; and pharmaceutical preparations for research and clinical use in protein degradation-based therapies targeting pathogenic proteins in diverse disease states.

Research and development in the pharmaceutical and biotechnology fields